Results 261 to 270 of about 462,772 (320)
Some of the next articles are maybe not open access.
Current Opinion in Endocrinology, Diabetes & Obesity, 2013
The aim of this study is to provide a thorough updated review of the diagnosis and treatment of postmenopausal osteoporosis.There have been several important findings in the field of postmenopausal osteoporosis over the past 1-2 years. Fewer morphometric vertebral fractures were found in women treated for 6 years with zoledronic acid compared with ...
Dima L, Diab, Nelson B, Watts
openaire +2 more sources
The aim of this study is to provide a thorough updated review of the diagnosis and treatment of postmenopausal osteoporosis.There have been several important findings in the field of postmenopausal osteoporosis over the past 1-2 years. Fewer morphometric vertebral fractures were found in women treated for 6 years with zoledronic acid compared with ...
Dima L, Diab, Nelson B, Watts
openaire +2 more sources
Current Osteoporosis Reports, 2004
The postmenopausal state is the most common underlying cause for osteoporosis and most of our understanding of the condition relates to this group. Recent evidence has suggested that hormone therapy may no longer have the pre-eminent place it once held but the same studies have also confirmed its antifracture efficacy. However, an increasing variety of
openaire +2 more sources
The postmenopausal state is the most common underlying cause for osteoporosis and most of our understanding of the condition relates to this group. Recent evidence has suggested that hormone therapy may no longer have the pre-eminent place it once held but the same studies have also confirmed its antifracture efficacy. However, an increasing variety of
openaire +2 more sources
Estrogen deficiency‐mediated osteoimmunity in postmenopausal osteoporosis
Medicinal research reviews (Print)Postmenopausal osteoporosis (PMO) is a common disease associated with aging, and estrogen deficiency is considered to be the main cause of PMO. Recently, however, osteoimmunology has been revealed to be closely related to PMO.
Yao Yao +4 more
semanticscholar +1 more source
Management of postmenopausal osteoporosis
European Journal of Obstetrics & Gynecology and Reproductive Biology, 1994More than 25% of postmenopausal women are at risk of osteoporosis. In order to avoid its consequences, it is necessary to find an appropriate prevention and/or treatment. We studied: (1) 15 postmenopausal women treated with percutaneous estradiol (50 micrograms/24 h) plus MPA (10 mg/10 days/month); (2) 15 postmenopausal women treated with synthetic ...
DI RENZO, Giancarlo +5 more
openaire +5 more sources
Postmenopausal Osteoporosis: A Review of Latest Guidelines.
Endocrinology and metabolism clinics of North America (Print)Osteoporosis is characterized by increased bone turnover and reduced bone mass, leading to skeletal fragility and heightened fracture risk. It is a growing public health concern with expectations for a continued significant rise of fractures by 50% in ...
Prathayini Subarajan +2 more
semanticscholar +1 more source
Southern Medical Journal, 1984
In 1980, the combined incidences of vertebral and hip fractures necessitating hospitalization of women living in Knox County, Tennessee nearly doubled each five years after the age of 50. These data led us to review the pathogenesis, diagnostic methods, and therapeutic measures used to control or minimize the occurrence of postmenopausal osteoporosis ...
A W, Diddle, I Q, Smith
openaire +2 more sources
In 1980, the combined incidences of vertebral and hip fractures necessitating hospitalization of women living in Knox County, Tennessee nearly doubled each five years after the age of 50. These data led us to review the pathogenesis, diagnostic methods, and therapeutic measures used to control or minimize the occurrence of postmenopausal osteoporosis ...
A W, Diddle, I Q, Smith
openaire +2 more sources
Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations.
Maturitas, 2021In postmenopausal women, osteoporosis may coexist with other metabolic diseases, including, but not limited to, obesity, diabetes, nonalcoholic fatty liver disease (NAFLD), dyslipidemia and cardiovascular disease (CVD).
S. Polyzos +4 more
semanticscholar +1 more source
Treatment of Postmenopausal Osteoporosis
JAMA, 2001POSTMENOPAUSAL OSTEOPOROSIS IS a common and serious clinical problem. As both individuals and society have come to recognize the importance of preventing and treating osteoporosis, several new medications have been developed that have been shown to reduce fracture rates in women with osteoporosis.
D, Altkorn, T, Vokes
openaire +2 more sources
▼Denosumab for postmenopausal osteoporosis?
Drug and Therapeutics Bulletin, 2012Osteoporosis is the most common clinical disorder of bone metabolism, and is characterised by low bone mass and deterioration of the microarchitecture of bone tissue that results in increased bone fragility and susceptibility to bone fracture.1 In the UK, it is estimated that osteoporosis affects over 3 million people and leads to 230,000 fractures per
openaire +2 more sources
Postmenopausal osteoporosis management
Current Opinion in Obstetrics and Gynecology, 2000Osteoporosis is perhaps the widest-ranging social, physical, and economic impact of estrogen deficiency. Postmenopausal bone loss is the major determinant of osteoporosis. Osteoporotic risk can be determined by measuring bone mineral density using dual X-ray absorptiometry.
M, Gambacciani, M, Ciaponi
openaire +2 more sources